DiaSorin S.p.A. (DSRLF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DiaSorin S.p.A. (DSRLF) Healthcare & Pipeline Overview

DiaSorin S.p.A., founded in 1968, is a global leader in immunodiagnostics and molecular diagnostics, offering a broad portfolio of testing kits and platforms. With a focus on infectious diseases and specialty diagnostics, DiaSorin serves diverse markets across Europe, the Americas, Asia Pacific, and China, maintaining a strong competitive position through strategic partnerships and innovative solutions.

What Is the Investment Thesis for DSRLF?

DiaSorin S.p.A. presents a notable research candidate within the diagnostics sector, supported by its strong market position, diversified product portfolio, and global reach. The company's focus on specialty diagnostics and infectious disease testing positions it favorably to capitalize on growing demand for advanced diagnostic solutions. With a P/E ratio of 22.97 and a profit margin of 15.8%, DiaSorin demonstrates solid profitability. Key growth catalysts include the expansion of its LIAISON platform, strategic partnerships, and entry into new geographic markets. However, investors may want to evaluate potential risks such as competition, regulatory changes, and fluctuations in currency exchange rates. The company's beta of 0.62 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

DSRLF Key Highlights

Market capitalization of $4.25B, reflecting its significant presence in the diagnostics market.

• P/E ratio of 22.97, indicating a potentially reasonable valuation relative to its earnings.
• Profit margin of 15.8%, demonstrating efficient operations and profitability.
• Gross margin of 65.7%, showcasing the company's ability to maintain strong pricing power and cost control.
• Dividend yield of 1.86%, providing a steady income stream for investors.

Who Are DSRLF's Competitors?

DSRLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DSRLF's Key Strengths?

Strong market position in immunodiagnostics and molecular diagnostics.

• Diversified product portfolio with a broad range of diagnostic tests.
• Global presence with direct operations in key markets.
• Proprietary LIAISON technology platform.

What Are DSRLF's Weaknesses?

Reliance on a limited number of key products.

• Exposure to regulatory risks and changes in healthcare policies.
• Competition from larger, more diversified players.
• Dependence on third-party suppliers for certain raw materials and components.

What Could Drive DSRLF Stock Higher?

Launch of new diagnostic tests for emerging infectious diseases in Q3 2026.

• Expansion of the LIAISON platform with new assays for autoimmune disorders.
• Strategic partnerships to expand product portfolio and geographic reach.
• Geographic expansion into emerging markets in Asia Pacific and Latin America.

What Are the Key Risks for DSRLF?

Intense competition from established players and new entrants in the diagnostics market.

• Price pressures from healthcare providers and payers.
• Technological obsolescence and the need for continuous innovation.
• Regulatory risks and changes in healthcare policies.
• Dependence on third-party suppliers for certain raw materials and components.

What Are the Growth Opportunities for DSRLF?

• Expansion of LIAISON Platform: DiaSorin can further expand its LIAISON platform by developing and launching new assays for emerging infectious diseases and specialty diagnostic areas. This includes assays for autoimmune disorders, bone and mineral metabolism, and gastrointestinal diseases. The global market for autoimmune disease diagnostics is projected to reach $12.7 billion by 2027, presenting a significant opportunity for DiaSorin to capture market share. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: DiaSorin can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborations with companies specializing in molecular diagnostics, point-of-care testing, or digital health solutions can enhance DiaSorin's competitive position and accelerate its growth. The company's existing partnerships with QIAGEN, TTP, and MeMed demonstrate its commitment to strategic collaborations. Timeline: Ongoing.
• Geographic Expansion: DiaSorin has opportunities to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where demand for diagnostic testing is growing rapidly. Establishing local manufacturing facilities, distribution networks, and sales teams in these regions can enable DiaSorin to better serve local customers and capitalize on growth opportunities. The Asia Pacific IVD market is projected to be the fastest-growing region, driven by increasing healthcare expenditure and rising awareness of diagnostic testing. Timeline: 2026-2028.
• Development of Point-of-Care Testing Solutions: DiaSorin can invest in the development of point-of-care testing (POCT) solutions that enable rapid and convenient diagnostic testing at the point of care, such as in physician's offices, emergency rooms, and pharmacies. POCT solutions can improve patient outcomes by enabling faster diagnosis and treatment decisions. The global POCT market is projected to reach $40 billion by 2028, driven by increasing demand for decentralized testing and technological advancements. Timeline: 2027-2030.
• Digital Health Integration: DiaSorin can integrate its diagnostic solutions with digital health platforms and data analytics tools to provide clinicians with comprehensive insights and decision support. This includes developing mobile apps, cloud-based platforms, and data analytics algorithms that can analyze patient data, identify trends, and personalize treatment plans. The integration of digital health technologies can improve patient engagement, enhance clinical efficiency, and drive better healthcare outcomes. Timeline: 2028-2030.

What Are DSRLF's Competitive Advantages?

• Proprietary LIAISON technology platform.
• Extensive portfolio of diagnostic tests.
• Global distribution network.
• Strong brand reputation in the diagnostics market.

What Does DSRLF Do?

DiaSorin S.p.A., established in 1968 and headquartered in Saluggia, Italy, is a global biotechnology company specializing in the development, production, and distribution of in-vitro diagnostics (IVD). The company operates in the immunodiagnostics and molecular diagnostics segments, providing a wide array of testing kits and platforms used in clinical laboratories worldwide. DiaSorin's product portfolio includes the LIAISON series of immunodiagnostic platforms (LIAISON XS, LIAISON XL, and LIAISON XL LAS) and the LIAISON MDX molecular diagnostics platform. These platforms are designed for the automated analysis of biological samples to detect and quantify various analytes, aiding in the diagnosis and monitoring of diseases. The company's tests cover a range of clinical areas, including infectious diseases, bone and mineral metabolism, hepatitis, retrovirus, and autoimmune disorders. DiaSorin has expanded its global presence through strategic partnerships and acquisitions, establishing a direct presence in key markets such as Europe, North America, and Asia. The company's commitment to innovation is reflected in its ongoing research and development efforts, aimed at expanding its product offerings and improving the performance of its diagnostic solutions. DiaSorin's business model focuses on providing high-value diagnostic solutions to clinical laboratories, hospitals, and research institutions, contributing to improved patient outcomes and healthcare efficiency.

What Products and Services Does DSRLF Offer?

• Develops and manufactures immunodiagnostic testing kits.
• Produces molecular diagnostic testing kits.
• Distributes diagnostic products globally.
• Offers LIAISON XS, LIAISON XL, and LIAISON XL LAS immunodiagnostic platforms.
• Provides the LIAISON MDX molecular diagnostics platform.
• Partners with other companies for diagnostic solutions.

How Does DSRLF Make Money?

• Develops and manufactures in-vitro diagnostic (IVD) kits and platforms.
• Sells diagnostic products to clinical laboratories, hospitals, and research institutions.
• Generates revenue through direct sales and distribution agreements.
• Invests in research and development to expand its product portfolio and improve its diagnostic solutions.

What Industry Does DSRLF Operate In?

DiaSorin operates within the global in-vitro diagnostics (IVD) market, which is characterized by continuous innovation and increasing demand for accurate and rapid diagnostic testing. The market is driven by factors such as the aging population, rising prevalence of chronic diseases, and technological advancements in diagnostic techniques. The competitive landscape includes major players such as CNVVF (Siemens Healthineers), CNVVY (Roche Holding AG), and FLMNF (Thermo Fisher Scientific), each offering a broad range of diagnostic solutions. DiaSorin differentiates itself through its focus on specialty diagnostics and its LIAISON platform, which offers a comprehensive menu of tests on a single instrument.

Who Are DSRLF's Key Customers?

• Clinical laboratories
• Research institutions
• Diagnostic centers

DiaSorin S.p.A. (DSRLF) Valuation Context

Valued at $4.25B, DSRLF is classified as a mid-cap stock. Relative to its peer group, DSRLF's quantitative score of 52/100 is below the peer average of 64/100.

DSRLF Revenue & Earnings Trend

In Q2 FY2026, DSRLF generated $697.4M in top-line revenue, marking a sequential increase of 109.4%. The company recorded net income of $97.3M, with diluted EPS of $1.74. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, DSRLF averaged $0.93 in diluted EPS.

Company Profile

DiaSorin S.p.A. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Saluggia, IT. The company is led by CEO Carlo Rosa. DSRLF has traded publicly since 2009.

Return on equity for DiaSorin S.p.A. stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.9%, showing how much profit it generates from its asset base. DSRLF trades at a trailing price-to-earnings ratio of 22.97, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 10.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.

DiaSorin S.p.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.71 places it in the grey zone, a middle ground that warrants monitoring.

DSRLF Financials

DSRLF Latest News

DSRLF Analyst Consensus

DSRLF MoonshotScore

What Investors Ask About DiaSorin S.p.A. (DSRLF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources